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egorical regression model. First the estimation procedure was
validated through estimation of the MAUF for the EQ-5D
attributes based on the exiting Spanish tariff scores for the instru-
ment. Secondly the MAUF for the SF-6D attributes was esti-
mated regressed on the EQ-5D tariff scores. Weights were
rescaled to yield scores ranging from worse possible state (0) to
full health (1). RESULTS: All estimated attribute weights were
signiﬁcant and goodness of ﬁt was reasonable (R2 = 0.799).
Spanish utility values for the same health states are signiﬁcantly
different from those used in the UK; 0.7458 (0.208) vs. 0.7090
(0.143), p < 0.001. The shape of utility scores obtained with the
Spanish MAUF exhibits a cubic pattern as compared to the
British. Utilities obtained by the Spanish MAUF are higher for
benign health states while severe states attain lower utilities.
CONCLUSION: The proposed method allows for a valid and
reliable estimation of a MAUF based on kwon utilities of a
concurrent instrument, avoiding the need of incomplete designs
to collect preferences. Evident differences between culture
speciﬁc scoring systems encourage adapting instruments to the
target culture in order to obtain valid measures. Spanish weights
for SF-6D are now available to be used with existing or new
SF-36v1 databases.
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OBJECTIVES: The efﬁcacy and safety of certolizumab pegol
(CZP), a PEGylated anti-TNF, in patients with active Crohn’s
disease (CD) have been demonstrated in two 26-week induction
and maintenance trials, PRECiSE 1 (Sandborn et al., 2005) and
PRECiSE 2 (Schreiber et al., 2005). This analysis evaluated the
effect of CZP versus placebo on quality-adjusted life-years
(QALYs) for each subject in these trials. METHODS: In
PRECiSE 1, patients with active CD received double-blind CZP
400 mg (n = 331) or placebo (n = 328) every 4 weeks after induc-
tion. PRECiSE 2 began with an open-label induction period
(CZP 400 mg at Weeks 0, 2 and 4). Patients who demonstrated
a clinical response at Week 6 were randomised to receive CZP
400 mg (n = 215) or placebo (n = 210) every 4 weeks from
Weeks 8 to 24. The EQ-5D was administered at each visit and
converted into utility scores using an established algorithm
(Dolan et al., 1995). An estimate of QALYs was made for each
patient from the area under the utility curve during the randomi-
sation period of each trial. Mean QALYs and standard deviation
(SD) were calculated by treatment group and compared using a
Wilcoxon rank sum test. RESULTS: Over the 26-week PRECiSE
1 trial, the mean (SD) QALYs were 0.5456 (0.2993) for CZP and
0.4797 (0.3121) for placebo. Similarly, between Weeks 6 and 26
of PRECiSE 2, the mean (SD) QALYs were 0.4976 (0.2047) in
the CZP group versus 0.4286 (0.2171) in the three injection
followed by placebo group. A statistically signiﬁcant gain in
QALYs with CZP was observed in both trials: PRECiSE 1 0.0659
(p = 0.001); PRECiSE 2 0.0690 (p = 0.015). CONCLUSION:
CZP improved both quality and quantity of remission and
response period, as measured by QALYs, signiﬁcantly more than
placebo among patients with CD in two 26-week maintenance
trials.
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OBJECTIVES: Non-steroidal anti-inﬂammatory drugs (NSAIDs)
and Aspirin are among the most widely used drugs, particularly
for long-term treatment of arthritic disorders in primary care.
Aspirin/NSAIDs cause upper-gastrointestinal symptoms. This
study aimed to assess the nature and frequency of Upper-GI
symptoms (GERD and/or Dyspepsia) experienced by patients
receiving Aspirin and/or NSAIDs and to depict the current clini-
cal practice in the ﬁeld of gastroprotection of patients receiving
these drugs. METHODS: A total of 1604 individuals (M/F:
743/861, age 58.3713.1 years, BMI 27.5  3.7 Kg/m2) visiting
189 Primary Care Practitioners between June-July 2006 were
included. A structured questionnaire was used to record
demographic/medical history data including Aspirin/NSAIDs
use, the antisecretory treatment received together with Aspirin/
NSAIDs and the presence of GERD (heartburn, regurgitation)
and Dyspepsia (epigastric pain, early satiety, postprandial full-
ness) symptoms, which were based on widely accepted epidemio-
logical criteria. RESULTS: The main indications for patients
receiving Aspirin/NSAIDs were backache (16.7%), osteoarthritis
(14.5%), coronary artery disease (8.9%) and rheumatoid arthri-
tis (5.6%). Upper-GI symptoms (GERD and/or Dyspepsia) for
2 days/week were reported by 71.7% of participants. GERD
was reported by 57.3% and Dyspepsia by 54.8% of participants,
while 40.3% of them experienced symptoms of both diseases.
Antisecretory treatment was used by 78.8% of participants (PPIs
75.8%, H2-antagonists 20.2%, Antacids 8.2%). Upper-GI
symptoms of 2 day’s per/week were reported by 70.5% of
patients who received antisecretory treatment compared to
76.8% of those who did not (P < 0.025). Patients receiving
PPI experienced upper-GI symptoms by 66.2%, signiﬁcantly
less compared to 83.9% of H2-antagonists/Antacids users
(P < 0.001). CONCLUSION: Upper-GI symptoms are present in
approximately 3/4 of Aspirin/NSAIDs users. Antisecretory treat-
ment reduces Upper-GI symptoms, with PPIs being signiﬁcantly
superior than H2–antagonists/Antacids. However, in primary
care, a substantial proportion of Aspirin/NSAIDs users remain
symptomatic despite the use of antisecratory agents and therefore
other parameters such as adherence to antisecratory treatment
should be further investigated.
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OBJECTIVES: To estimate demand and supply of blood prod-
ucts in Bavaria, as due to intransparency on prices and trade
volumes reliable data are missing and to support optimal plan-
ning of blood supply and usage in Bavaria within the next two
decades. METHODS: Data were collected through desk-top
researches on demographics (e.g. Federal Statistical Ofﬁce
Germany, Bavarian State Ofﬁce for Statistics and Data Process-
ing), blood usage and donation behaviour in Germany (Robert
Koch Institute, Paul-Ehrlich-Institute, Bavarian Red Cross) and
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